Study tracks 'post hospital syndrome' in patients undergoing elective outpatient surgery

Patients who have been hospitalized in the last 90 days and then have elective outpatient surgery are much more likely to be readmitted to the hospital within 30 days of undergoing that surgery, according to a recent study by researchers from Loyola University.

Paul C. Kuo, MD, chair of the department of surgery at Loyola University Medical Center and Loyola University Chicago Stritch School of Medicine, and colleagues presented their findings about this condition—known as “post hospital syndrome” (PHS)—at the Western Surgical Association annual meeting in Napa Valley, Calif.

“Surgeons must consider all recent inpatient admissions when risk-stratifying patients for ambulatory, elective surgery,” the authors concluded, according to a Loyola University Health System press release.

The Loyola study looked at the records of more than 57,000 patients who underwent hernia repair in 2011, and more than 1,000 of those patients had PHS.

More than 7 percent of patients with PHS had to be readmitted to the hospital within 30 days of elective outpatient hernia surgery. The percentage of patients without PHS who had to be readmitted following the same procedure was 1.6.

Some potential explanations for this relationship between PHS and being readmitted after elective outpatient surgery include sleep deprivation as a result of hospitalization, impactful medications taken during hospitalization, and the fact that some patients may be asked to fast before certain surgeries or tests, which affects the body’s nutrition. 

Michael Walter
Michael Walter, Managing Editor

Michael has more than 18 years of experience as a professional writer and editor. He has written at length about cardiology, radiology, artificial intelligence and other key healthcare topics.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.